newsfilter
← Latest News
GlobeNewswire·

BiondVax CEO Issues Letter to Shareholders

JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic